Recommendations Developed for Treating Hypercalcemia of Malignancy
Authors strongly recommend treatment with denosumab or an intravenous bisphosphonate for adults with HCM
Authors strongly recommend treatment with denosumab or an intravenous bisphosphonate for adults with HCM
In preclinical studies, WP1122 has shown to increase cellular uptake of 2-DG, increase drug half-life, and increase the ability to cross the blood brain barrier.
No increased perioperative morbidity seen among patients with local regionally advanced oral cavity squamous cell carcinoma
Findings seen in studies involving patients receiving chemoradiotherapy for nonmetastatic squamous cell carcinoma of head and neck
Silmitasertib is a first-in-class potent and highly selective inhibitor of casein kinase 2 (CK2).
The phase 3 RATIONALE 309 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in 263 adults with recurrent or metastatic nasopharyngeal cancer (RM-NPC).
The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies.
Study authors analyzed the safety and efficacy of using MMA for patients undergoing head and neck surgery.
However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only